2026-11-09 · 2026-11 / week-2
Koppers prices a margin reset; its 2027 recovery still lacks a number
Koppers prices a margin reset; its 2027 recovery still lacks a number
Summary: Koppers closed at $29.97 on Nov. 6, down 24.4% after Q3 adjusted EBITDA fell 18.2% year over year and FY26 EBITDA guidance fell 9.2% at the midpoint. Free-cash-flow guidance rose, but management tied the improvement to working-capital actions while saying input and logistics costs would persist through year-end. The 2027 recovery is a claim without a quantified guide. Reject / no trade: the reference-only base is flat, a credible price stress is worse than -5%, and no executable entry is verified.
Opportunity Ranking
| Rank | Candidate | Direction | Mispricing | Evidence Freshness | Catalyst Window | Positioning | 10/5 Status | Tradeability | Main Rejection Risk |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Koppers (KOP) | Long | A 24.4% post-result decline followed a 9.2% cut to the FY26 EBITDA-guide midpoint; the lower share price may still reflect real leverage and margin risk. | Nov. 6 SEC release and Form 10-Q | FY26 close and first quantified FY27 guide; exact date unverified | No direct positioning evidence; price and volume only | Reject: 0% base, at least -16.6% stress | Reference close only; live gates unverified | Raw-material pressure and weak end markets may outlast price increases and cost actions. |
| 2 | Eton Pharmaceuticals (ETON) | Long | Revenue grew 158% and guidance rose, but the stock gained 19.8% on Nov. 6 and AnovoRx represents 93.8% of nine-month product sales. | Nov. 5 issuer release and 10-Q | Q4/FY26 results; date unverified | No direct flows or ownership evidence | No sourced 10% base with a bounded downside | Reference close only | Strong growth does not establish value after the gap; tax benefit and distributor concentration matter. |
| 3 | Berkshire Hathaway B (BRK.B) | Long | Q3 operating earnings fell 5.8%; insurance underwriting earnings fell 42.9%, but other operating businesses rose and the report was released Saturday. | Nov. 7 issuer release and Form 10-Q | First post-report regular session, Nov. 9 | Buybacks are disclosed; broader positioning unknown | No demonstrated 10/5 long | Friday close predates the report | No post-report price acceptance or company-specific 10% base is established. |
Selected for this no-trade screen: KOP, for the freshest price, earnings-guide and cash-flow disagreement. It is the highest-information rejection in this comparison, not the best executable opportunity.
Why this one now: KOP reported before the latest completed U.S. session. The price fell much more than the revised EBITDA guide midpoint, yet the company still has net debt of $845.4 million and no numerical FY27 forecast. That combination makes both overreaction and justified repricing plausible.
What should surprise the reader: Nine-month operating cash flow rose to $126.9 million and company-defined free cash flow to $92.0 million. The filing says working-capital improvement reflected the timing of customer receipts and vendor payments and lower inventory; it does not show that weaker segment margins have reversed.
Why This Is the Best Opportunity Right Now
This is a research ranking, not a trade ranking. KOP has a new SEC filing, a sharp price response, quantified guide changes and a near-term test of management's 2027 recovery claim. The operating bridge is measurable even though the answer is not yet favorable to a long.
ETON has better reported growth, but its Nov. 6 rally has already capitalized a large part of the positive surprise. Its 10-Q says AnovoRx generated 93.8% of nine-month product sales and 95.0% of receivables at Sept. 30. Berkshire's Q3 results are fresh but were released on Saturday; its Nov. 6 close cannot show how the market accepted them. Neither comparator has a better evidenced long payoff.
No independent consensus estimate or pre-release market-implied EBITDA expectation was verified. The article therefore does not claim that KOP's fall was excessive or that its current price is cheap.
Why This Can Move More Than 5% Soon
Koppers says higher raw-material and logistics costs are expected to persist through the rest of 2026, while commercial actions and production-network changes are expected to improve 2027 results. A filed FY27 guide that quantifies those actions could change the earnings path by more than 5% of the share price. The same mechanism works against the long if input costs or weaker end demand delay the recovery.
The next useful test is not another price bounce. It is the Q4/FY26 report and first quantified FY27 outlook: realized pricing, segment EBITDA, volume, cost-out, working capital, free cash flow and net debt. The exact release date was not verified. Until then, the size and timing of the proposed recovery remain unknown.
10/5 Asymmetry Gate
- Reference basis: $29.97 KOP regular-session close, Nov. 6, 2026, 4:00 p.m. EST; entry is not verified.
- Favorable base move: 0.0%, below the required +10%.
- Adverse stress: at least -16.6% to a historical price marker; losses below it remain possible, so the -5% bound fails.
- Gross base-to-adverse ratio: 0.0:1 before costs. The 10/5 gate fails.
The full price-only scenario map follows below. I do not combine the Nov. 6 quote with the Sept. 30 debt balance and Oct. 30 share count to manufacture an enterprise-value target; those dates do not share one valuation timestamp. Scenario weights are judgment, not measured frequencies.
The Setup
Koppers sells treated wood products, wood-preservation chemicals and carbon materials. In Q3, sales rose 2.8% to $499.1 million, while adjusted EBITDA fell 18.2% to $58.0 million and adjusted EPS fell 36.4% to $0.77. Net income declined 38.2% to $14.7 million. Revenue growth therefore did not translate into earnings growth.
The segment split is more informative than the consolidated sales line. Railroad and Utility Products and Services adjusted EBITDA fell 23.6%; Carbon Materials and Chemicals fell 60.9%; Performance Chemicals rose 13.4%. Koppers attributed the weaker results mainly to raw-material and logistics costs, lower crosstie pricing and lower utilization at Carbon Materials and Chemicals. Performance Chemicals benefited from higher volume and utilization, partly offset by higher raw-material costs.
The 10-Q reported a nine-month GAAP net loss of $125.7 million. Its non-GAAP reconciliation included $233.4 million of impairment, restructuring and plant-closure costs. The cash-flow statement separately added back $210.2 million of impairment and depreciation in impairment and restructuring. These are different lines and should not be added together. The charges are not equivalent to current-period cash outflow, but they show that the operating reset has involved real asset and restructuring decisions.
The Market Price
KOP closed at $29.97 on Nov. 6, down $9.67 or 24.39% from Nov. 5. The session range was $26.86 to $33.51. Yahoo Finance reports 354,300 shares traded; ChartExchange reports 354,557. The closes and ranges agree; the volume counts differ slightly and are not averaged. SPY rose 0.31% that day, so the KOP move was not a broad-market decline.
This is the latest completed regular-session close. At publication time, New York has not reopened after the weekend. There is no current bid, ask, spread, depth, venue-quality, volume-quality or exit-liquidity observation. The Friday close is research context only.
The Mispricing
The price-positioning-catalyst disagreement is clear enough to screen, but not to call a long mispricing. The share price fell 24.4% in the session while FY26 adjusted EBITDA guidance fell 9.2% at the midpoint. Adjusted EPS guidance fell 20.6% at the midpoint. That gap could indicate that the market also lowered the expected 2027 recovery, discount rate or valuation multiple. It is not proof of overreaction: debt can make a smaller change in enterprise value produce a larger percentage change in common equity.
The company cut FY26 adjusted EBITDA guidance from $240–$250 million to $220–$225 million. The midpoint moved from $245 million to $222.5 million. The Q2 release's current forecast matches the Q3 release's prior forecast; there is no source conflict. Adjusted EPS guidance fell from $3.80–$4.20 to $3.10–$3.25. Operating-cash-flow guidance stayed at $165–$185 million, while capex guidance fell from $55 million to $50 million. Free-cash-flow guidance rose from $110–$130 million to $115–$135 million. The FCF increase is not evidence that the earnings cut has reversed.
The strongest long interpretation is that the price move discounts a prolonged trough even though Koppers says 2027 commercial changes and cost actions can improve results. The strongest opposing interpretation is that those benefits are unquantified and may not offset cost inflation or weaker end markets. The observed filings support the opposing case more strongly today.
The Positioning
Direct evidence of crowded ownership, short interest, borrow, options exposure, fund flows or forced selling was not verified. Nov. 6 volume and price show a large one-day reaction, not who sold or why. Issuer disclosures say Koppers repurchased $51.0 million of common stock during the first nine months and reduced debt, but those completed actions do not establish current investor positioning or a share-price floor.
Positioning confidence is low. No short-covering, capitulation or forced-flow thesis is used.
The Catalyst
| Step | State | Test | Failure path |
|---|---|---|---|
| FY26 close | Announced guidance, not yet realized | Compare Q4 revenue, segment EBITDA, adjusted EPS, working capital, capex and net debt with the revised guide. | Another miss would confirm that cash and earnings pressure persist. |
| 2027 commercial actions | Management expectation; terms and dollar effect not quantified | Require a company guide that separates pricing, cost reductions, volume and segment contribution. | Price increases may arrive late, be offset by raw materials or reduce demand. |
| Cash conversion | Nine-month results reported; repeatability unproved | Reconcile receivables, inventory, payables and accrued liabilities to CFO and FCF. | A working-capital reversal could lower cash generation even if EBITDA stabilizes. |
The cheapest falsification test is the next filing's segment bridge and working-capital table. A price recovery without those figures would not confirm the thesis.
The Payoff
The question is not whether KOP can bounce. It is whether the highest-probability base clears +10% while the adverse path stays within -5%. The reference map below does neither. Its price levels are history markers, not fair value or limits on loss; execution costs cannot be estimated from current evidence.
Price Target and Probability Map
The common working horizon is nine months, through the next full-year report and FY27 outlook; the issuer has not verified an exact release date. The numbers below use historical price markers because the latest quote, share count and debt balance do not share one valuation timestamp.
| Scenario | Probability | Target / Level | Return / Payoff | Horizon | Conditions | Evidence Quality |
|---|---|---|---|---|---|---|
| Top Case | 20% | $39.64, Nov. 5 close | +32.3% | 9 months | The next guide quantifies a 2027 margin recovery and the market retraces the pre-report close. | Low; recovery is not quantified. |
| Base Case | 50% | $29.97, Nov. 6 close | 0.0% | 9 months | FY26 is delivered near the revised guide, but no confirmed FY27 improvement supports a re-rating. | Medium for the current reference; low for the future path. |
| Bottom Case | 30% | $25.00, Nov. 7, 2025 intraday low | -16.6% | 9 months | Costs or demand worsen and the share price retests its prior 52-week low. Prices below this marker remain possible. | Low; historical reference, not a floor. |
| Invalidation | n/a | A filed FY27 outlook and operating bridge materially alter the earnings path | n/a | At next FY report | Re-underwrite only from reported segment results, pricing, cost actions, cash conversion and debt. | Medium once filed. |
Probability-weighted expected value: $30.41 per share, +1.5% gross from $29.97 before costs. Weights are subjective; this is not a fair-value estimate or a calibrated forecast.
Current market level and timestamp: $29.97, KOP, Nov. 6, 2026, regular close (21:00 UTC).
Primary instrument: Common stock, for research comparison only.
10/5 favorable base move: 0.0%.
10/5 credible adverse move: At least -16.6% to the prior low marker; the tail below it is unbounded.
10/5 measurement basis: Reference-only; no verified entry.
10/5 status: Reject.
Confidence: Low. Price levels are observable; scenario probabilities and the next-year path are not.
The Kill Shot
The strongest counterargument is that there is no identifiable mispricing. The guide was reduced, segment results diverged, and management warned of continuing input and logistics pressure. The market may be discounting an unquantified recovery rationally rather than overshooting.
The load-bearing long assumption is that 2027 price increases and operating actions convert into recurring EBITDA and cash faster than costs and demand deteriorate. Management has not quantified that bridge. Even if recovery comes, delay, weaker volumes, a working-capital reversal or a lower valuation can still leave the share price below today's reference.
What Could Go Wrong
- Raw-material and logistics costs remain higher for longer or cannot be recovered through pricing.
- Lower end-market demand, crosstie pricing or feedstock quality further weakens RUPS or Carbon Materials and Chemicals.
- The strong nine-month cash-flow comparison reverses as customer receipts and vendor payments normalize.
- Further impairments or restructuring costs consume management attention and reduce the credibility of adjusted measures.
- Current net debt and the absence of a quantified 2027 guide leave equity exposed to downside beyond the observed $25 marker.
- A halt, gap or weak exit market can bypass any hypothetical stop; no stop is treated as protection.
What Would Prove This Wrong
Reopen the long only after filed Q4/FY26 results and FY27 guidance quantify higher segment EBITDA from pricing and cost actions, show that working-capital cash gains are not the sole source of improved FCF, and demonstrate stable or falling net debt. Then rebuild the price map from a fresh regular-session quote and time-matched share and debt data. A bounce alone does not invalidate this rejection.
Risk Audit
- What the market may already know: The Nov. 6 release disclosed lower profit, a reduced EBITDA/EPS guide, higher input and logistics costs, a raised FCF guide and management's 2027 improvement claim.
- What remains unknown: Analyst consensus at the release, current beneficial ownership, short interest, borrow, options/dealer exposure, fund flows, and the independent market's expected 2027 EBITDA.
- Balance sheet: Sept. 30 cash was $42.8 million and total debt $888.2 million, for $845.4 million net debt. The facility-defined net-leverage ratio was 3.5x and interest coverage 4.4x; these are company calculations, not a same-date valuation bridge.
- Cash quality: Nine-month CFO was $126.9 million, FCF $92.0 million and capex $34.9 million. The filing attributes part of the CFO improvement to timing of customer receipts, vendor payments and lower inventory. Do not treat the record cash result as a recurring run rate.
- Valuation risk: No independent consensus target or same-date enterprise-value bridge was verified. Price markers are historical references, not fair value, support or a floor.
- Execution risk: Friday's close is stale for an order. Current quote, spread, depth, venue quality, volume quality and exit liquidity are unverified. Gaps, halts and slippage remain possible.
Best Trade Strategy
No trade. Keep entry.price null and execution.can_execute=false. Do not turn the $39.64 prior close, $25 historical low or scenario values into an order or price floor. Reassess after the next filed results and FY27 guide; require fresh quote, spread, depth, venue and volume quality, plus realistic exit capacity. No options, leverage, margin or market-order strategy was evaluated.
Sources
- Koppers Q3 2026 results and revised FY26 outlook — SEC Exhibit 99.1, Nov. 6, 2026
- Koppers Form 10-Q for quarter ended Sept. 30, 2026 — SEC
- Koppers Q2 2026 results and prior FY26 outlook — issuer release, Aug. 6, 2026
- KOP historical prices, including Nov. 6 close — Yahoo Finance
- KOP historical prices, including Nov. 6 close and Nov. 7, 2025 low — ChartExchange
- ETON Q3 2026 results and raised FY26 outlook — issuer release, Nov. 5, 2026
- Eton Form 10-Q for quarter ended Sept. 30, 2026 — SEC
- ETON historical prices — issuer's historical price lookup
- Berkshire Q3 2026 earnings release, Nov. 7
- Berkshire Form 10-Q for quarter ended Sept. 30, 2026
- BRK.B historical prices, including Nov. 6 close — StockAnalysis / S&P Global
- SPY historical daily prices, Nov. 6 close — Investing.com
Research Quality Scorecard
| Criterion | Score | Evidence and deduction |
|---|---|---|
| Market disagreement | 3/5 | Price and guide changes are explicit; pre-release consensus and expected 2027 EBITDA are unknown. |
| Evidence base | 4/5 | Fresh SEC release/filing and confirmed close; no same-date EV bridge or consensus data. |
| Positioning and flows | 2/5 | Issuer repurchases and price/volume are observed; broader ownership and flows are not. |
| Catalyst path | 3/5 | 2027 actions are announced but not quantified or dated; the next reporting test is observable. |
| Payoff architecture | 2/5 | Historical price markers and subjective weights are transparent, but they are not valuation targets. |
| Invalidation discipline | 4/5 | Segment margins, guide, working capital and net debt provide monitorable tests. |
| Differentiated insight | 4/5 | Separates improved cash generation from weaker segment earnings and the timing of working capital. |
| Client value | 4/5 | Shows why a sharp drop does not prove a bargain and what evidence would change the decision. |
| Total | 26/40 | Publishable no-trade screen; the score does not override the failed 10/5 gate. |
Bottom Line
Koppers' guide reset is real; its 2027 recovery is not yet measurable. Better nine-month cash flow and debt reduction offer a credible countercase, but working-capital timing, weaker segment EBITDA and 3.5x net leverage leave the downside open. The latest close offers no +10% base case and the historical stress is worse than -5%. Reject the long and wait for filed evidence.
AI Illustration Prompt
Editorial illustration: a steel rail switchyard running through a chemical-treatment plant at dusk. One track is marked “FY26 guide” and slopes lower; a second, labeled “2027 recovery,” remains unfinished beyond the yard lights. A small ledger in the foreground separates “EBITDA,” “working capital” and “net debt.” Muted charcoal, oxidized copper, timber brown and restrained cream, no logos, no charts or price arrows, ample negative space, subtle readable “The Mispricing Desk” watermark.